CL2015002456A1 - Tratamiento de la deficiencia de la hormona del crecimiento pediátrica con análogos de la hormona del crecimiento humano - Google Patents

Tratamiento de la deficiencia de la hormona del crecimiento pediátrica con análogos de la hormona del crecimiento humano

Info

Publication number
CL2015002456A1
CL2015002456A1 CL2015002456A CL2015002456A CL2015002456A1 CL 2015002456 A1 CL2015002456 A1 CL 2015002456A1 CL 2015002456 A CL2015002456 A CL 2015002456A CL 2015002456 A CL2015002456 A CL 2015002456A CL 2015002456 A1 CL2015002456 A1 CL 2015002456A1
Authority
CL
Chile
Prior art keywords
growth hormone
pediatric
treatment
human
xten
Prior art date
Application number
CL2015002456A
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey L Cleland
George M Bright
Eric Humphriss
Original Assignee
Amunix Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Operating Inc filed Critical Amunix Operating Inc
Publication of CL2015002456A1 publication Critical patent/CL2015002456A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CL2015002456A 2013-03-11 2015-09-02 Tratamiento de la deficiencia de la hormona del crecimiento pediátrica con análogos de la hormona del crecimiento humano CL2015002456A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361776618P 2013-03-11 2013-03-11
US201361810786P 2013-04-11 2013-04-11
US201361835002P 2013-06-14 2013-06-14
US201361880701P 2013-09-20 2013-09-20
US201361911731P 2013-12-04 2013-12-04
US201461931987P 2014-01-27 2014-01-27
US201461948457P 2014-03-05 2014-03-05

Publications (1)

Publication Number Publication Date
CL2015002456A1 true CL2015002456A1 (es) 2016-05-27

Family

ID=51658905

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002456A CL2015002456A1 (es) 2013-03-11 2015-09-02 Tratamiento de la deficiencia de la hormona del crecimiento pediátrica con análogos de la hormona del crecimiento humano

Country Status (16)

Country Link
US (1) US20160158321A1 (enExample)
EP (1) EP2968451A4 (enExample)
JP (3) JP2016514132A (enExample)
KR (1) KR20150124955A (enExample)
CN (1) CN105209055A (enExample)
AU (1) AU2014249258A1 (enExample)
BR (1) BR112015022257A8 (enExample)
CA (1) CA2900949A1 (enExample)
CL (1) CL2015002456A1 (enExample)
EA (1) EA201591529A1 (enExample)
HK (1) HK1216617A1 (enExample)
IL (1) IL240392A0 (enExample)
MX (1) MX2015012175A (enExample)
PH (1) PH12015502063A1 (enExample)
SG (1) SG11201506732YA (enExample)
WO (1) WO2014164568A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2016109823A1 (en) * 2015-01-02 2016-07-07 Amunix Operation Inc. Treatment of pediatric growth hormone deficiency with human growth hormone analogues
EP3229671A4 (en) 2015-02-03 2018-04-04 Apple Inc. Family sleep monitoring system
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017136583A1 (en) 2016-02-02 2017-08-10 Versartis, Inc. Growth hormone treatment adherence system
RU2732113C2 (ru) 2016-02-17 2020-09-11 Дженексин, Инк. Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста
JOP20190019A1 (ar) 2016-08-30 2019-02-12 Genexine Inc تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
WO2019126576A1 (en) 2017-12-21 2019-06-27 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
US11903683B2 (en) 2018-08-03 2024-02-20 Chelak Medical Solutions Inc Non-barometric determination of hemodynamic effects of cardiac arrhythmias using signals sensed by an implantable device
RU2753191C2 (ru) * 2019-09-26 2021-08-12 Федеральное государственное бюджетное учреждение науки Институт Биологии Развития им. Н.К. Кольцова Российской Академии Наук Новый рекомбинантный аналог гормона роста пролонгированного действия
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
KR102599111B1 (ko) * 2020-01-31 2023-11-07 울산대학교 산학협력단 인슐린유사성장인자-1 융합단백질 및 이의 용도
CA3185680A1 (en) * 2020-07-22 2022-01-27 Nicola Ammer A screening method for diagnosing growth hormone deficiency in pediatric patients by using macimorelin
CN115925994B (zh) 2020-09-30 2023-09-22 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
JP2025512832A (ja) 2022-03-30 2025-04-22 ベイジン キューエル バイオファーマシューティカル カンパニー,リミテッド ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2393828T3 (pl) * 2009-02-03 2017-06-30 Amunix Operating Inc. Wydłużone rekombinowane polipeptydy i zawierające je kompozycje
ES2544982T3 (es) * 2009-09-02 2015-09-07 Merck Serono S.A. Método para predecir el nivel de respuesta al crecimiento
CA2875827A1 (en) * 2012-06-05 2013-12-12 Amunix Operating Inc. Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency

Also Published As

Publication number Publication date
WO2014164568A1 (en) 2014-10-09
US20160158321A1 (en) 2016-06-09
SG11201506732YA (en) 2015-09-29
KR20150124955A (ko) 2015-11-06
BR112015022257A2 (pt) 2017-10-10
HK1216617A1 (zh) 2016-11-25
JP2017101074A (ja) 2017-06-08
EP2968451A1 (en) 2016-01-20
JP2016514132A (ja) 2016-05-19
EA201591529A1 (ru) 2016-04-29
PH12015502063A1 (en) 2016-01-25
AU2014249258A1 (en) 2015-08-27
CA2900949A1 (en) 2014-10-09
EP2968451A4 (en) 2017-01-04
JP2019056013A (ja) 2019-04-11
BR112015022257A8 (pt) 2018-01-23
MX2015012175A (es) 2016-01-12
CN105209055A (zh) 2015-12-30
IL240392A0 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
CL2015002456A1 (es) Tratamiento de la deficiencia de la hormona del crecimiento pediátrica con análogos de la hormona del crecimiento humano
EP4003458A4 (en) Unilateral-driven drug infusion device
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
BR112015026325A2 (pt) dosagem oral de compostos glp-1
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
EA201991484A1 (ru) Лекарственные формы энзалутамида
MX2016008013A (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp.
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
MX373851B (es) Métodos de administración de tratamiento con pirfenidona.
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
IL285440A (en) Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly
EA201390745A1 (ru) Активируемая пользователем автономная выполненная в едином корпусе система доставки лекарственного средства посредством ионофореза
WO2014153385A3 (en) Methods of treating metabolic disorders
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
EA201391689A1 (ru) Система доставки лекарственного средства
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX377510B (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
MX2016000103A (es) Dispositivo de administracion de farmaco oral y metodos de uso del mismo.
EP2880160A4 (en) ISOLATION OF TRAFFIC-REINFORCING MUTANTS OF AN ACTIVE-SPREADING PROTEIN
PL3648788T3 (pl) Leczenie krwawienia z przewodu pokarmowego u pacjentów z ciężką chorobą von willebranda poprzez podanie rekombinowanego vwf
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
BR112015028890A2 (pt) derivados de piridona para o tratamento de infecções virais e outras doenças
EA201591603A1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах